Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Hirotsugu UemuraGaku AraiHiroji UemuraHiroyoshi SuzukiJunya AoyamaTomoyoshi HatayamaMiku ItoFlorence LefresneSharon McCarthySuneel MundleJin HeKim N ChiPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
The efficacy of apalutamide with androgen deprivation therapy in Japanese patients was consistent with efficacy demonstrated in the overall population. No new safety concerns emerged with long-term follow-up.